Skip Navigation


Annals of Oncology Advance Access originally published online on March 8, 2006
Annals of Oncology 2006 17(5):769-772; doi:10.1093/annonc/mdl027
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
17/5/769    most recent
mdl027v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ferreri, A. J. M.
Right arrow Articles by Ponzoni, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferreri, A. J. M.
Right arrow Articles by Ponzoni, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa

A. J. M. Ferreri1,*, E. Viale2, M. Guidoboni3, A. Giordano Resti4, C. De Conciliis5, L. Politi6, A. A. Lettini3, F. Sacchetti3, R. Dolcetti3, C. Doglioni7 and M. Ponzoni7

1 Medical Oncology, 2 Gastroenterology, 4 Ophthalmology, 6 Neuroradiology, and 7 Pathology Units, San Raffaele H Scientific Institute, Milan, Italy; 3 Immunovirology and Biotherapy Unit, Department of Pre-Clinical and Epidemiological Research, Centro di Riferimento Oncologico, IRCCS National Cancer Institute, Aviano, Italy; 5 Ophthalmology Unit, Ospedale San Giuseppe, Milan, Italy

* Correspondence to: Dr A. J. M. Ferreri, Medical Oncology Unit, Dept. of Oncology, San Raffaele H Scientific Institute, Via Olgettina 60, 20132 Milan, Italy. Tel: +39-02-26437649; Fax: +39-02-26437603; E-mail: andres.ferreri{at}hsr.it

Background: A pathogenic link between hepatitis C virus (HCV) and MALT-type lymphomas has been suggested. However, studies assessing the role of HCV infection separately in different forms of MALT lymphomas are not available.

Patients and methods: The prevalence and clinical implications of HCV seropositivity were analyzed in 55 patients with ocular adnexa lymphoma (OAL) of MALT-type.

Results: HCV seropositivity was detected in seven (13%) patients. At presentation, HCV infection was significantly associated with concomitant extra-orbital disease, lymph node dissemination and involvement of additional extranodal organs. HCV seropositivity was associated also with a higher relapse rate and worse progression-free survival. In fact, 16 patients experienced relapse after first-line treatment: five (71%) were HCV-seropositive and 11 (23%) were HCV-seronegative, with a median TTP of 31 and 50+ months (P = 0.01), and a 5-year progression-free survival of 43 ± 18% and 77 ± 7% (P = 0.005), respectively. HCV-seropositive patients experienced frequent relapses despite further lines of therapy; relapses were systemic in all cases but one; multiple subcutaneous nodules were common at relapse.

Conclusions: HCV seropositivity is present in 13% of OAL of MALT-type. Concomitant HCV infection is associated with more disseminated disease and aggressive behavior in OAL, with a consequent potential negative impact in patients managed with radiotherapy alone.

Key words: MALT lymphoma, ocular adnexal lymphoma, hepatitis C virus, infectious agents


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
A. J. M. Ferreri, R. Dolcetti, M.-Q. Du, C. Doglioni, A. Giordano Resti, L. S. Politi, C. De Conciliis, J. Radford, F. Bertoni, E. Zucca, et al.
Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy
Ann. Onc., May 1, 2008; 19(5): 835 - 846.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E.-K. Song, S.-Y. Kim, T. M. Kim, K.-W. Lee, T. Yun, I.-I. Na, H. Shin, S. H. Lee, D. W. Kim, S. I. Khwarg, et al.
Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma
Ann. Onc., February 1, 2008; 19(2): 242 - 246.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P Arnaud, M-C Escande, M Lecuit, P Validire, C Levy, C Plancher, A Vincent-Salomon, N Brousse, P de Cremoux, O Hermine, et al.
Hepatitis C virus infection and MALT-type ocular adnexal lymphoma
Ann. Onc., February 1, 2007; 18(2): 400 - 401.
[Full Text] [PDF]

Home page
 Ann OncolHome page
L Arcaini, S Burcheri, A Rossi, M Paulli, R Bruno, F Passamonti, E Brusamolino, A Molteni, A Pulsoni, M. Cox, et al.
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT
Ann. Onc., February 1, 2007; 18(2): 346 - 350.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Ferreri, R Dolcetti, P Musto, G. Dognini, C Doglioni, and M Ponzoni
Reply to the article 'Hepatitis C virus (HCV) infection and MALT-type ocular adnexal lymphoma (OAL)' by P. Arnaud, M.-C. Escande, M. Lecuit et al. (Ann Oncol doi:10.1093/annonc/mdl369)
Ann. Onc., February 1, 2007; 18(2): 401 - 403.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. J. M. Ferreri, M. Ponzoni, M. Guidoboni, A. G. Resti, L. S. Politi, S. Cortelazzo, J. Demeter, F. Zallio, A. Palmas, G. Muti, et al.
Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial.
J Natl Cancer Inst, October 4, 2006; 98(19): 1375 - 1382.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. Decaudin, P. de Cremoux, A. Vincent-Salomon, R. Dendale, and L. L.-L. Rouic
Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options
Blood, September 1, 2006; 108(5): 1451 - 1460.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.